Log in to your Inderes Free account to see all free content on this page.
Calliditas Therapeutics
206.2 SEK 0%6 investors are following this company
Calliditas Therapeutics operates in the pharmaceutical industry. The company is specialized in the research and development of medical products, particularly aimed at treating kidney and liver diseases. Examples of specialist areas include squamous cell carcinoma, autoimmune hepatitis, and nephropathy. The company was founded in 2004 and has operations on a global level, with headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CALTX
Daily low / high price
206.2 / 206.8
SEK
Market cap
12.36B SEK
Turnover
28.27M SEK
Volume
137K
Latest videos
Financial calendar
Interim report
13.08.2024
Interim report
11.11.2024
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
BVF Partners LP | 10.5 % | 11.7 % |
Linc AB (Bengt Julander) | 10.0 % | 11.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
![Calliditas Therapeutics, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0fdc296-d621-41b2-97f7-59065f50463e.png)
Calliditas Therapeutics, Audiocast with teleconference, Q2'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics: Calliditas provides setanaxib patent update
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
![Calliditas Therapeutics R&D Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/89810995-6d01-4c29-bbd5-b044cdebe1b7.png)
Calliditas Therapeutics R&D Day, 2024
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Redeye: Calliditas Q1 - Powerful launch momentum
![Calliditas Therapeutics, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/583b15ce-1bac-4662-ba0b-38cba9bb0c76.png)